Benchmark Reiterates Speculative Buy Rating for Anebulo Pharmaceuticals (NASDAQ:ANEB)

Anebulo Pharmaceuticals (NASDAQ:ANEB)‘s stock had its “speculative buy” rating restated by research analysts at Benchmark in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $8.00 price objective on the stock. Benchmark’s price objective points to a potential upside of 426.32% from the stock’s previous close.

Anebulo Pharmaceuticals Stock Performance

Shares of Anebulo Pharmaceuticals stock opened at $1.52 on Tuesday. The company’s fifty day simple moving average is $1.89 and its two-hundred day simple moving average is $2.10. The company has a market cap of $39.42 million, a P/E ratio of -5.07 and a beta of -1.00. Anebulo Pharmaceuticals has a 12-month low of $1.46 and a 12-month high of $3.30.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last announced its quarterly earnings results on Wednesday, September 25th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08. Analysts predict that Anebulo Pharmaceuticals will post -0.52 EPS for the current fiscal year.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.